Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Verve Therapeutics, Inc. - Common Stock
(NQ:
VERV
)
11.13
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jul 24, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Verve Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Verve Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – VERV
September 17, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against WEBTOON, Verve, and Ardelyx and Encourages Investors to Contact the Firm
September 13, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Verve Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – VERV
September 13, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
Faruqi & Faruqi Reminds Verve Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 - VERV
September 13, 2024
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Shareholder Rights Attorneys Robbins LLP Reminds VERV Stockholders of the Opportunity to Lead the Verve Therapeutics, Inc. Class Action
September 10, 2024
From
Robbins LLP
Via
Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against WEBTOON, Verve, and Ardelyx and Encourages Investors to Contact the Firm
September 09, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Verve Therapeutics, Inc. (NASDAQ: VERV); Investors with Losses Encouraged to Discuss Their Options with Counsel
September 09, 2024
From
DiCello Levitt LLP
Via
GlobeNewswire
VERV SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Verve Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
September 09, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics
September 06, 2024
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Verve Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – VERV
September 05, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
VERV Class Action Notice: Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the Verve Therapeutics, Inc. Class Action
September 04, 2024
From
Robbins LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CAE, Verve, and MongoDB and Encourages Investors to Contact the Firm
September 03, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
September 03, 2024
From
Verve Therapeutics
Via
GlobeNewswire
VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
September 03, 2024
From
Schall Law
Via
GlobeNewswire
REMINDER – Verve Therapeutics, Inc. Investor Alert: Robbins LLP Reminds Shareholders of the VERV Class Action Lawsuit
September 03, 2024
From
Robbins LLP
Via
Business Wire
VERVE THERAPEUTICS, INC. (NASDAQ: VERV) INVESTOR ALERT: Investors With Large Losses in Verve Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
September 03, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
VERV SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Verve Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
September 01, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics
August 29, 2024
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
August 29, 2024
From
The Schall Law Firm
Via
Business Wire
VERVE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Verve Therapeutics, Inc. and Encourages Investors to Contact the Firm
August 28, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Stockholder Notice: Robbins LLP Informs Stockholders of the Class Action Filed Against Verve Therapeutics, Inc.
August 28, 2024
From
Robbins LLP
Via
GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics
August 27, 2024
From
Faruqi & Faruqi, LLP
Via
Business Wire
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Verve Therapeutics, Inc. – VERV
August 27, 2024
From
Rosen Law Firm
Via
Business Wire
10 Health Care Stocks Whale Activity In Today's Session
↗
August 19, 2024
Via
Benzinga
VERV Stock Earnings: Verve Therapeutics Beats EPS, Beats Revenue for Q2 2024
↗
August 08, 2024
VERV stock results show that Verve Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Verve Therapeutics Announces Pipeline Progress and Reports Second Quarter 2024 Financial Results
August 08, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
August 02, 2024
From
Verve Therapeutics
Via
GlobeNewswire
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
↗
July 05, 2024
A number of companies are working on new drugs for high lipids, including cholesterol and triglycerides.
Via
Investor's Business Daily
Cathie Wood's Ark Invest Dumps Another $3.25M Worth Of Tesla Shares Amid Searing Q2 Deliveries Rally
↗
July 03, 2024
Via
Benzinga
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
July 01, 2024
From
Verve Therapeutics
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
